Small-Molecule Targeting of Oncogenic FTO Demethylase in Acute Myeloid Leukemia.
Huang, Y; Su, R; Sheng, Y; Dong, L; Dong, Z; Xu, H; Ni, T; Zhang, ZS; Zhang, T; Li, C; et al.
Cancer Cell.
2019;
35:677-691.e10.
Alternative translation initiation generates the N-terminal truncated form of RUNX1 that retains hematopoietic activity.
Goyama, S; Schibler, J; Mulloy, JC.
Experimental Hematology.
2019;
72:27-35.
Improved multilineage human hematopoietic reconstitution and function in NSGS mice.
Wunderlich, M; Chou, F; Sexton, C; Presicce, P; Chougnet, CA; Aliberti, J; Mulloy, JC.
PLoS ONE.
2018;
13:e0209034-e0209034.
Comparative utility of NRG and NRGS mice for the study of normal hematopoiesis, leukemogenesis, and therapeutic response.
Barve, A; Casson, L; Krem, M; Wunderlich, M; Mulloy, JC; Beverly, LJ.
Experimental Hematology.
2018;
67:18-31.
METTL14 Inhibits Hematopoietic Stem/Progenitor Differentiation and Promotes Leukemogenesis via mRNA m(6)A Modification.
Weng, H; Huang, H; Wu, H; Qin, X; Zhao, BS; Dong, L; Shi, H; Skibbe, J; Shen, C; Hu, C; et al.
Cell Stem Cell.
2018;
22:191-205.e9.
R-2HG Exhibits Anti-tumor Activity by Targeting FTO/m(6)A/MYC/CEBPA Signaling.
Su, R; Dong, L; Li, C; Nachtergaele, S; Wunderlich, M; Qing, Y; Deng, X; Wang, Y; Weng, X; Hu, C; et al.
Cell.
2018;
172:90-105.e23.
Cell polarity and division symmetry analyses in transformed blood cells.
Mizukawa, B; O’Brien, E; Mulloy, JC; Zheng, Y.
Methods in molecular biology (Clifton, N.J.).
2018;
1821:257-266.
Targeted inhibition of STAT/TET1 axis as a therapeutic strategy for acute myeloid leukemia.
Jiang, X; Hu, C; Ferchen, K; Nie, J; Cui, X; Chen, C; Cheng, L; Zuo, Z; Seibel, W; He, C; et al.
Nature Communications.
2017;
8.
Agonistic targeting of TLR1/TLR2 induces p38 MAPK-dependent apoptosis and NFκB-dependent differentiation of AML cells.
Eriksson, M; Peña-Martínez, P; Ramakrishnan, R; Chapellier, M; Högberg, C; Glowacki, G; Orsmark-Pietras, C; Velasco-Hernandez, T; Lazarevic, VL J; Juliusson, G; et al.
Blood Advances.
2017;
1:2046-2057.
The cell polarity determinant CDC42 controls division symmetry to block leukemia cell differentiation.
Mizukawa, B; O'Brien, E; Moreira, DC; Wunderlich, M; Hochstetler, CL; Duan, X; Liu, W; Orr, E; Grimes, HL; Mulloy, JC; et al.
Blood.
2017;
130:1336-1346.